PMID- 34694236
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211126
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Electronic)
IS  - 1929-0748 (Linking)
VI  - 10
IP  - 10
DP  - 2021 Oct 25
TI  - Automated Virtual Reality Cognitive Therapy for People With Psychosis: Protocol 
      for a Qualitative Investigation Using Peer Research Methods.
PG  - e31742
LID - 10.2196/31742 [doi]
LID - e31742
AB  - BACKGROUND: Many people with psychosis experience difficulties in everyday social 
      situations. Anxiety can make life challenging, leading to withdrawal. Cognitive 
      therapy, using active in vivo learning, enables people to overcome fears. These 
      treatments are not readily available to people with psychosis. Automated virtual 
      reality (VR) therapy is a potential route to increase accessibility. The 
      gameChange automated VR cognitive therapy is designed to help people overcome 
      anxious avoidance and build confidence in everyday social situations. A virtual 
      coach guides the person through the treatment. Understanding user experience is 
      key to facilitating future implementation. Peer research methods, in which people 
      with lived experience of the issues being studied are involved in collecting and 
      analyzing data, may be useful in developing this understanding. This encourages 
      researchers to draw on their lived experience to explore participant perspectives 
      and co-create knowledge. OBJECTIVE: The primary objective is to use a peer 
      research approach to explore the participant experience of a novel automated VR 
      therapy for anxious social avoidance. This includes understanding (1) the 
      experience of anxious social avoidance in people with psychosis, (2) the 
      experience of the gameChange automated VR cognitive therapy, and (3) any 
      potential impact of the therapy in people's lives. This will inform future 
      implementation strategies. The secondary objective is to explore how peer 
      research can be used to co-create knowledge. METHODS: Semistructured interviews 
      will be conducted with approximately 25 people with psychosis participating in 
      the gameChange trial (ISRCTN17308399). Participants will be recruited from the 
      five trial centers based in National Health Service mental health trusts across 
      England. Interviews will be conducted by two researchers. One is a peer 
      researcher with similar lived experience to the trial participants. The other has 
      lived experiences of mental health issues that do not directly overlap with those 
      of the trial participants. Interview questions will focus on an individual's 
      experience of anxious social avoidance, experiences of participating in the 
      gameChange VR therapy, and any changes or impact following therapy. The interview 
      schedule was developed in collaboration with the gameChange Lived Experience 
      Advisory Panel (LEAP), comprising 10 project advisors with lived experience of 
      psychosis. Interpretative phenomenological analysis and template analysis will be 
      used to explore individual accounts. The LEAP will contribute to the analysis. 
      RESULTS: Data collection will be conducted from April to September 2021, and 
      analysis will be conducted from June to October 2021. As of September 28, 2021, 
      20 participants had been interviewed, and coding is underway. CONCLUSIONS: The 
      study, employing a peer research approach, may provide a unique insight into the 
      experiences of anxious social avoidance in people with psychosis and its 
      treatment using automated VR therapy. This will inform potential future 
      implementation of VR automated therapies in mental health services. INTERNATIONAL 
      REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/31742.
CI  - (c)Jessica Bond, Dan Robotham, Alexandra Kenny, Vanessa Pinfold, Thomas Kabir, 
      Humma Andleeb, Michael Larkin, Jennifer L Martin, Susan Brown, Aislinn D Bergin, 
      Ariane Petit, Laina Rosebrock, Sinead Lambe, Daniel Freeman, Felicity Waite. 
      Originally published in JMIR Research Protocols 
      (https://www.researchprotocols.org), 25.10.2021.
FAU - Bond, Jessica
AU  - Bond J
AUID- ORCID: 0000-0002-0685-3317
AD  - McPin Foundation, London, United Kingdom.
FAU - Robotham, Dan
AU  - Robotham D
AUID- ORCID: 0000-0003-2968-2415
AD  - McPin Foundation, London, United Kingdom.
FAU - Kenny, Alexandra
AU  - Kenny A
AUID- ORCID: 0000-0002-0162-9009
AD  - McPin Foundation, London, United Kingdom.
FAU - Pinfold, Vanessa
AU  - Pinfold V
AUID- ORCID: 0000-0003-3007-8805
AD  - McPin Foundation, London, United Kingdom.
FAU - Kabir, Thomas
AU  - Kabir T
AUID- ORCID: 0000-0001-8908-0964
AD  - McPin Foundation, London, United Kingdom.
FAU - Andleeb, Humma
AU  - Andleeb H
AUID- ORCID: 0000-0001-5410-7725
AD  - Research Department of Clinical, Educational and Health Psychology, Psychology 
      and Language Sciences, Faculty of Brain Sciences, UCL, London, United Kingdom.
FAU - Larkin, Michael
AU  - Larkin M
AUID- ORCID: 0000-0003-3304-7000
AD  - School of Psychology, Aston University, Birmingham, United Kingdom.
FAU - Martin, Jennifer L
AU  - Martin JL
AUID- ORCID: 0000-0001-7392-1749
AD  - School of Medicine, University of Nottingham, Nottingham, United Kingdom.
AD  - National Institute for Health Research Nottingham Biomedical Research Centre, 
      Nottingham, United Kingdom.
AD  - National Institute for Health Research Mindtech Co-operative, Nottingham, United 
      Kingdom.
FAU - Brown, Susan
AU  - Brown S
AUID- ORCID: 0000-0002-3403-3180
AD  - School of Medicine, University of Nottingham, Nottingham, United Kingdom.
AD  - National Institute for Health Research Nottingham Biomedical Research Centre, 
      Nottingham, United Kingdom.
AD  - National Institute for Health Research Mindtech Co-operative, Nottingham, United 
      Kingdom.
FAU - Bergin, Aislinn D
AU  - Bergin AD
AUID- ORCID: 0000-0002-4276-3466
AD  - School of Medicine, University of Nottingham, Nottingham, United Kingdom.
AD  - National Institute for Health Research Nottingham Biomedical Research Centre, 
      Nottingham, United Kingdom.
AD  - National Institute for Health Research Mindtech Co-operative, Nottingham, United 
      Kingdom.
FAU - Petit, Ariane
AU  - Petit A
AUID- ORCID: 0000-0001-6026-9616
AD  - Department of Psychiatry, University of Oxford, Oxford, United Kingdom.
AD  - Oxford Health National Health Service Foundation Trust, Oxford, United Kingdom.
AD  - National Institute for Health Research Oxford Health Biomedical Research Centre, 
      Oxford, United Kingdom.
FAU - Rosebrock, Laina
AU  - Rosebrock L
AUID- ORCID: 0000-0002-4583-8435
AD  - Department of Psychiatry, University of Oxford, Oxford, United Kingdom.
AD  - Oxford Health National Health Service Foundation Trust, Oxford, United Kingdom.
AD  - National Institute for Health Research Oxford Health Biomedical Research Centre, 
      Oxford, United Kingdom.
FAU - Lambe, Sinead
AU  - Lambe S
AUID- ORCID: 0000-0001-9543-8109
AD  - Department of Psychiatry, University of Oxford, Oxford, United Kingdom.
AD  - Oxford Health National Health Service Foundation Trust, Oxford, United Kingdom.
AD  - National Institute for Health Research Oxford Health Biomedical Research Centre, 
      Oxford, United Kingdom.
FAU - Freeman, Daniel
AU  - Freeman D
AUID- ORCID: 0000-0002-2541-2197
AD  - Department of Psychiatry, University of Oxford, Oxford, United Kingdom.
AD  - Oxford Health National Health Service Foundation Trust, Oxford, United Kingdom.
AD  - National Institute for Health Research Oxford Health Biomedical Research Centre, 
      Oxford, United Kingdom.
FAU - Waite, Felicity
AU  - Waite F
AUID- ORCID: 0000-0002-2749-1386
AD  - Department of Psychiatry, University of Oxford, Oxford, United Kingdom.
AD  - Oxford Health National Health Service Foundation Trust, Oxford, United Kingdom.
AD  - National Institute for Health Research Oxford Health Biomedical Research Centre, 
      Oxford, United Kingdom.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
DEP - 20211025
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC8576557
OTO - NOTNLM
OT  - agoraphobia
OT  - cognitive therapy
OT  - implementation
OT  - mental health
OT  - peer research
OT  - psychosis
OT  - qualitative methods
OT  - schizophrenia
OT  - therapy
OT  - virtual reality
COIS- Conflicts of Interest: DF is a founder and nonexecutive board director of Oxford 
      VR, a University of Oxford spin-out company, which programmed and commercializes 
      the gameChange treatment. DF holds equity in Oxford VR. SL does consultancy work 
      for Oxford VR. The McPin Foundation will receive an IP payment from Oxford VR due 
      to their role in the therapy development for the gameChange study.
EDAT- 2021/10/26 06:00
MHDA- 2021/10/26 06:01
PMCR- 2021/10/25
CRDT- 2021/10/25 12:18
PHST- 2021/07/02 00:00 [received]
PHST- 2021/08/03 00:00 [accepted]
PHST- 2021/08/02 00:00 [revised]
PHST- 2021/10/25 12:18 [entrez]
PHST- 2021/10/26 06:00 [pubmed]
PHST- 2021/10/26 06:01 [medline]
PHST- 2021/10/25 00:00 [pmc-release]
AID - v10i10e31742 [pii]
AID - 10.2196/31742 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2021 Oct 25;10(10):e31742. doi: 10.2196/31742.